Internal Medicine, Nephrology · Fresno, CA
NPI
1801864020
Since 2006
Specialty
Internal Medicine, Nephrology
Code 207RN0300X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
568 E Herndon Ave Ste 201
Fresno, CA, 93720
Phone (559) 228-6600
Groups this clinician bills Medicare through
Medicare paid, 2024
$341K
15,223 services
Medicare patients, 2024
781
Average age 74
Drug cost, 2024
$820K
2,246 prescriptions
Company payments, 2025
$417
From 11 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Harpreet S Dhindsa was code J0885 (injection, epoetin alfa, (for non-esrd use), 1000 units), 2,218 times for 63 patients. In total Harpreet S Dhindsa billed 15,223 services in 65 codes, and Medicare paid $341K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2017-08-15.
| Code |
|---|
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2,218 | 63 | $6.19 | $14K |
| 99232 Hospital E&M - Subsequent | Facility | 884 | 225 | $61.57 | $54K |
| 36415 Venipuncture Blood Collection | Office | 591 | 260 | $8.61 | $5,087 |
| 99214 Office E&M - Established | Office | 576 | 317 | $64.04 | $37K |
| 80053 Clinical Chemistry | Office | 504 | 257 | $10.32 | $5,200 |
| 84100 Clinical Chemistry | Office | 504 | 256 | $4.63 | $2,336 |
| 83735 Clinical Chemistry | Office | 501 | 255 | $6.55 | $3,281 |
| 85046 Blood Count | Office | 441 | 239 | $5.43 | $2,393 |
| 85025 Blood Count | Office | 426 | 242 | $7.56 | $3,221 |
| 82570 Clinical Chemistry | Office | 425 | 245 | $5.06 | $2,151 |
| 84156 Clinical Chemistry | Office | 404 | 238 | $3.59 | $1,448 |
| 83970 Clinical Chemistry | Office | 385 | 223 | $40.28 | $16K |
| 82043 Clinical Chemistry | Office | 369 | 228 | $5.63 | $2,079 |
| 90960 ESRD Related Services (not dialysis) | Office | 349 | 66 | $280.11 | $98K |
| 82306 Clinical Chemistry | Office | 323 | 234 | $28.94 | $9,346 |
By year: 2022 $390K for 13,826 services; 2023 $349K for 21,649 services; 2024 $341K for 15,223 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 591 | 260 | $8.61 | $5,087 |
| 84100 Clinical Chemistry | 504 | 256 | $4.63 | $2,336 |
| 80053 Clinical Chemistry | 504 | 257 | $10.32 | $5,200 |
| 83735 Clinical Chemistry | 501 | 255 | $6.55 | $3,281 |
| 85046 Blood Count | 441 | 239 | $5.43 | $2,393 |
| 85025 Blood Count | 426 | 242 | $7.56 | $3,221 |
| 82570 Clinical Chemistry | 425 | 245 | $5.06 | $2,151 |
| 84156 Clinical Chemistry | 404 | 238 | $3.59 | $1,448 |
| 83970 Clinical Chemistry | 385 | 223 | $40.28 | $16K |
| 82043 Clinical Chemistry | 369 | 228 | $5.63 | $2,079 |
Medicare prescription drug claims, 2024
In 2024, the drug Harpreet S Dhindsa prescribed most often to Medicare patients was Amlodipine Besylate, with 187 prescriptions and refills. In total Harpreet S Dhindsa wrote 2,246 Medicare prescriptions that cost $820K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Amlodipine Besylate Generic | 187 | 553 | 73 | $1,512 |
| Hydralazine Hcl Generic | 154 | 376 | 52 | $2,305 |
| Carvedilol Generic | 136 | 372 | 50 | $1,480 |
| Furosemide Generic | 119 | 304 | 52 | $906 |
| Calcitriol Generic | 119 | 327 | 38 | $1,651 |
| Losartan Potassium Generic | 115 | 345 | 48 | $1,077 |
| Sevelamer Carbonate Generic | 91 | 157 | 36 | $26K |
| Prosol Parenteral Amino Acid 20% No.1 | 88 | 88 | Under 11 | $22K |
| Farxiga Dapagliflozin Propanediol | 84 | 192 | 30 | $102K |
| Metoprolol Succinate Generic | 83 | 236 | 34 | $1,202 |
| Calcium Acetate Generic | 65 | 119 | 26 | $6,248 |
| Allopurinol Generic | 65 | 156 | 20 | $520 |
| Kerendia Finerenone | 57 | 127 | 19 | $80K |
| Veltassa Patiromer Calcium Sorbitex | 48 | 86 | 18 | $82K |
| Lisinopril Generic | 47 | 141 | 22 | $527 |
Brand drugs: 440 claims; generic drugs: 1,806 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Harpreet S Dhindsa $417 ($417 in general payments such as food, travel and fees) from 11 companies. The largest payer was Amgen Inc. with $106.
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. AMGN | 6 | $106 |
| Travere Therapeutics, Inc. TVTX | 5 | $99.05 |
| Mallinckrodt Hospital Products Inc. | 3 | $51.37 |
| Akebia Therapeutics Inc AKBA | 2 | $44.76 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 2 | $34.65 |
| Kyowa Kirin, Inc. 4151.T | 1 | $27.61 |
| Aurinia Pharma U.S., Inc. AUPH | 1 | $22.5 |
| Otsuka America Pharmaceutical, Inc. 4578.T | 1 | $16.05 |
| Lilly USA, LLC LLY | 1 | $15 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.